First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults
Jack N. Hutter*, Paul M. Robben, Christine Lee, Melinda Hamer, James E. Moon, Kristen Merino, Lei Zhu, Heather Galli, Xiaofei Quinn, Dallas R. Brown, Elizabeth Duncan, Jessica Bolton, Xiaoyan Zou, Evelina Angov, David E. Lanar, Mangala Rao, Gary R. Matyas, Zoltan Beck, Elke Bergmann-Leitner, Lorraine A. SoissonNorman C. Waters, Viseth Ngauy, Jason Regules, Sheetij Dutta
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
14Scopus
citations
Fingerprint
Dive into the research topics of 'First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults'. Together they form a unique fingerprint.